AI-Driven Retinal Screening Device Market Size & Share 2026-2035

AI-Driven Retinal Screening Device Market Size

The AI-Driven Retinal Screening Device Market was valued at USD 2.13 billion in 2025, is expected to reach USD 2.45 billion in 2026, and is forecast to expand at approximately 11.4% CAGR (2026–2035), reaching USD 6.45 billion by 2035.

The AI-Driven Retinal Screening Device Market is evolving from specialist-centered image interpretation toward distributed screening models that combine imaging hardware, autonomous diagnostic software, and cloud-enabled workflow tools. Demand is increasingly shaped by the ability to place retinal screening within diabetes management, primary care, pharmacy, and mobile-service pathways rather than relying solely on ophthalmology referrals.

AI-Driven Retinal Screening Device Market Trends, Growth Drivers & GMI Forecast Outlook

Diabetes screening mandates, aging-related ocular disease, and regulatory progress for autonomous diagnostic software are widening the addressable screening base. Forecast performance nevertheless depends on reimbursement, regulatory-market access, connectivity, data-governance capability, and whether providers can embed retinal imaging into routine care workflows without adding referral friction.

Key Drivers

*Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.*

Diabetes is commercially consequential because retinal examinations must become repeatable care events rather than episodic specialist procedures. Autonomous screening can move image capture nearer to the diabetes visit, reducing the operational gap between screening eligibility and completed examination. This favors vendors that can combine simple image acquisition, dependable referral logic, and integration with longitudinal care records.

Age-related disease broadens the clinical value of each imaging encounter. Providers are more likely to support premium imaging and software investment when a single workflow can identify multiple retinal risks, support monitoring decisions, and create an actionable referral pathway. The resulting demand favors systems that preserve diagnostic confidence across varied patient populations and image-quality conditions.

Regulatory authorization has changed the deployment proposition for retinal AI from assisted interpretation to autonomous screening in defined use settings. The commercial implication is not merely faster diagnosis; it is a wider set of buyers, including primary-care networks, retail health operators, and mobile-service organizations that require standardized workflows without continuous specialist review.

Key Restraints

*Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.*

Regulatory divergence makes international expansion a sequencing exercise rather than a simple replication of a successful home-market launch. Evidence packages, clinical validation expectations, software-change controls, and post-market obligations vary by jurisdiction, increasing the advantage of vendors with regulatory resources, multicountry evidence, and adaptable quality-management systems.

Infrastructure barriers are equally material where screening need is greatest. Portable devices and edge-enabled analytics can reduce dependence on fixed clinical infrastructure, but sustainable deployment still requires procurement funding, trained operators, referral capacity, and an economically viable service model. This makes public-health partnerships and locally appropriate device economics central to uptake.

Data-governance obligations add recurring operational work after initial deployment. Providers must be confident that image handling, algorithm monitoring, documentation, and accountability processes fit their clinical and legal environment, particularly where cloud-based delivery crosses organizational or geographic boundaries.

AI-Driven Retinal Screening Device Market Segment Analysis

By Technology

Fundus Image-Based AI accounted for 55% of total revenue in 2025 and is projected to reach USD 3.22 billion by 2035.The AI-Driven Retinal Screening Device Market continues to rely on fundus-based workflows as the practical entry point for distributed diabetic retinopathy screening. Familiar imaging practices, broad device availability, and compatibility with portable formats make this technology well suited to primary care, community programs, and referral-oriented screening networks. Its strategic challenge is to retain workflow simplicity as buyers increasingly expect broader disease coverage.

OCT-Based AI is projected to reach USD 2.19 billion by 2035 and expand at approximately 11.9% CAGR (2026–2035).OCT-based systems address care settings where disease monitoring, structural retinal assessment, and specialist-grade decision support matter more than maximum deployment breadth. Their role is reinforced by recurring monitoring needs in retinal and glaucoma care, where automation can reduce image-review workload and improve consistency across longitudinal scans. The segment is therefore positioned around clinical depth and high-acuity workflow value.

Multi-Modal AI generated USD 277 million in 2025 and is projected to capture 16% of global revenue by 2035.Multi-modal platforms are gaining relevance because they consolidate disease screening and monitoring into a more information-dense clinical encounter. Their commercial case is strongest where providers can justify a higher-value imaging workflow through multiple indications, referral pathways, or chronic-care programs. Adoption will depend on whether added diagnostic breadth outweighs integration complexity and capital requirements.

By Application

Diabetic Retinopathy represented 58% of global revenue in 2025 and is forecast to reach USD 3.29 billion by 2035.Diabetic retinopathy remains the foundational application because it connects retinal imaging directly to an established chronic-disease management obligation. Its importance extends beyond screening volume: the application has created the regulatory, reimbursement, and workflow infrastructure that other retinal AI use cases can leverage. Expansion into primary care is likely to preserve its role as the market's principal platform application.

AMD is projected to reach USD 1.10 billion by 2035 and advance at approximately 11.4% CAGR (2026–2035).AMD demand is supported by the need to identify risk earlier and manage disease progression with timely imaging insight. AI-enabled interpretation is especially relevant where clinicians must review recurring scans and distinguish clinically meaningful changes efficiently. This positions AMD as an important source of recurring utilization for higher-specification imaging and analytics platforms.

Glaucoma generated USD 299 million in 2025 and is projected to represent 16% of global revenue by 2035.Glaucoma screening benefits from AI's ability to support structured assessment of optic nerve and retinal features before visual impairment becomes apparent to patients. The application's appeal lies in earlier case finding and more scalable surveillance, particularly where specialist capacity is constrained. Providers will favor tools that fit referral protocols and can demonstrate consistency across real-world image conditions.

Cataract is projected to generate USD 387 million by 2035 and represented a 6% global share in 2025.Cataract-oriented AI screening is most relevant in high-volume environments where case identification and referral triage remain uneven. The application can support preventive outreach and community screening by reducing dependence on specialist grading at the initial encounter. Its commercial progress will be linked to the capacity of local care systems to convert identified need into surgical evaluation and treatment.

Other applications, including ROP, cardiovascular biomarker detection, and neurological indications, generated USD 106 million in 2025 and are projected to expand at approximately 17.9% CAGR (2026–2035).

This group represents the market's most consequential adjacency opportunity because it expands retinal imaging beyond conventional ophthalmic disease detection. Oculomics-based use cases could introduce new buyers in preventive care, cardiometabolic management, neurology, and research, although clinical validation, regulatory pathways, and payment models will determine which use cases progress beyond pilots.

By End Use

Hospitals accounted for 48% of global revenue in 2025 and are projected to reach USD 2.84 billion by 2035.Hospitals remain the central purchasing environment for integrated imaging platforms because they combine specialist expertise, imaging infrastructure, and complex referral networks. Enterprise procurement increasingly favors solutions that can connect ophthalmology, diabetes care, geriatrics, and electronic health records. This channel will remain strategically important even as screening activity shifts toward lower-acuity settings.

Ophthalmology Clinics are projected to account for 32% of global revenue by 2035 and expand at approximately 10.8% CAGR (2026–2035).Ophthalmology clinics are positioned as the quality-intensive segment of the market, emphasizing specialist review, disease monitoring, and management of referred patients. AI can increase scan throughput and standardize analysis, but purchasing decisions remain tied to diagnostic utility, interoperability, and the ability to complement rather than disrupt clinician judgment. The channel's value is likely to concentrate in complex and recurring-care use cases.

Mobile Clinics and Rural Camps generated USD 256 million in 2025 and are projected to expand at approximately 14.5% CAGR (2026–2035).Mobile deployment is a key route to reaching populations that do not regularly access specialist eye care. Handheld imaging, autonomous decision support, and portable operating models can make screening viable in rural and underserved settings, provided referral and follow-up pathways are in place. The segment's performance will be shaped by public-health funding, device durability, operator training, and connectivity choices.

Other end uses, including retail optometry, corporate wellness, and research, are projected to generate USD 516 million by 2035 and represented a 6% global share in 2025.This channel broadens retinal AI into preventive and consumer-adjacent settings where screening may occur before a formal eye-care encounter. Retail and wellness models can create new access points, while research use cases support biomarker development and evidence generation. Commercial success will require careful management of referral responsibility, clinical messaging, and data-governance expectations.

AI-Driven Retinal Screening Device Market Regional Analysis

North America AI-Driven Retinal Screening Device Market Analysis

North America accounted for a 43% revenue share in 2025 and is projected to reach USD 2.45 billion by 2035. The AI-Driven Retinal Screening Device Market in North America benefits from mature clinical infrastructure, established autonomous-AI market access, and a relatively developed reimbursement environment. Growth is increasingly tied to expanding deployment beyond specialist clinics into primary care, endocrinology, pharmacy, and other settings that can capture screening opportunities closer to routine chronic-disease care.

U.S.

The U.S. generated USD 826 million in 2025 and is projected to reach USD 2.16 billion by 2035. The U.S. remains the region's pivotal commercial market because regulatory precedent, reimbursement pathways, and large provider networks can accelerate adoption once workflows are validated. Competition centers on embedding autonomous screening into care pathways without creating uncompensated operational work for physicians, staff, or referring specialists.

Canada

Canada is projected to reach USD 294 million by 2035 and expand at approximately 12.3% CAGR (2026–2035). Canada offers a meaningful expansion opportunity for vendors that can align retinal AI with provincially organized chronic-disease programs and community-care delivery. Adoption is likely to favor models that demonstrate equitable access, reliable referral coordination, and compatibility with public-sector procurement priorities.

Europe AI-Driven Retinal Screening Device Market Analysis

Europe generated USD 512 million in 2025 and is projected to account for 22% of global revenue by 2035. European demand is shaped by population-health incentives, regulatory requirements, and the ability to deploy compliant platforms across varied national health systems. The region's opportunity is significant for vendors that can navigate conformity assessment, data-governance expectations, and country-specific procurement processes while offering scalable workflows for public screening programs.

Germany

Germany generated USD 102 million in 2025 and is projected to expand at approximately 11.3% CAGR (2026–2035). Germany's combination of specialist capacity, established clinical infrastructure, and a substantial chronic-disease burden supports steady adoption of retinal AI. Market development depends on proving value within ambulatory ophthalmology and ensuring that digital tools fit reimbursement and documentation expectations in routine clinical practice.

UK

The UK is projected to generate USD 383 million by 2035 and accounted for a 27% share of European revenue in 2025. The UK has a strong institutional basis for AI-assisted retinal screening because population-level diabetic eye screening is already embedded in care delivery. The key opportunity lies in modernizing grading and referral workflows while preserving national consistency, clinical oversight, and equitable patient access across regional service structures.

France

France generated USD 87 million in 2025 and is projected to expand at approximately 10.1% CAGR (2026–2035). France's adoption trajectory is influenced by the evidence and reimbursement requirements applied to AI-enabled diagnostic technologies. Once clinical and economic value is established, the country's broad insurance coverage and ophthalmology network can support scaled deployment, particularly where AI helps address screening capacity without compromising clinical governance.

Italy

Italy is projected to generate USD 165 million by 2035 and accounted for a 14% share of European revenue in 2025. Italy's aging population creates a broad clinical rationale for retinal screening across diabetic and age-related ocular conditions. Deployment will vary by region because healthcare infrastructure and digital readiness are not uniform, favoring vendors that can support both hospital-centered programs and locally tailored outreach models.

Spain

Spain generated USD 56 million in 2025 and is projected to expand at approximately 10.8% CAGR (2026–2035). Spain's universal-care system creates a route to broad adoption when retinal AI is integrated into recognized screening and referral protocols. The market opportunity is strongest for solutions that help primary-care teams identify risk consistently while linking patients efficiently to specialist follow-up.

Netherlands

The Netherlands is projected to generate USD 190 million by 2035 and expand at approximately 12.6% CAGR (2026–2035). The Netherlands offers favorable conditions for retinal AI because digitally connected healthcare workflows can support integration of imaging, analytics, and referral data. Its innovation-oriented provider base also makes the country a useful commercial entry point for suppliers seeking to demonstrate interoperability and establish evidence in the broader Benelux market.

Asia Pacific AI-Driven Retinal Screening Device Market Analysis

Asia Pacific accounted for 25% of global revenue in 2025 and is projected to represent 30% by 2035. Asia Pacific combines large unmet diabetes-screening needs with highly varied healthcare maturity, creating multiple adoption paths for retinal AI. Developed markets emphasize specialist-grade systems and chronic-care integration, while emerging markets prioritize affordability, portability, and public-health reach. Local platform development and national digitization programs are reshaping the competitive balance.

China

China is projected to generate USD 948 million by 2035 and accounted for a 51% share of Asia Pacific revenue in 2025. China is central to regional market development because domestic AI providers, large healthcare networks, and chronic-disease prevention priorities can support deployment at substantial scale. Local vendors possess an advantage where they understand procurement practices, workflow requirements, and the operational needs of hospital and community-health settings.

Japan

Japan generated USD 107 million in 2025 and is projected to expand at approximately 12.5% CAGR (2026–2035). Japan's aging demographics make efficient screening and longitudinal management of retinal disease strategically important. Demand is likely to center on technologies that support high-quality imaging, specialist productivity, and reliable integration into tightly regulated clinical pathways, particularly for age-related disease monitoring.

India

India is projected to generate USD 464 million by 2035 and expand at approximately 15.8% CAGR (2026–2035). India presents a distinctive opportunity because large screening gaps coexist with price sensitivity and an expanding digital-health infrastructure. Vendors that design for handheld deployment, constrained connectivity, scalable operator training, and public-health procurement are better placed than suppliers attempting to transplant high-cost developed-market models without adaptation.

Australia

Australia generated USD 28 million in 2025 and is projected to expand at approximately 13.0% CAGR (2026–2035). Australia's dispersed population gives teleretinal and AI-supported screening a practical role in extending specialist access beyond major urban centers. Adoption will be reinforced by solutions that connect primary care, remote services, and ophthalmology referral pathways while maintaining image quality and clinical accountability.

South Korea

South Korea is projected to generate USD 79 million by 2035 and expand at approximately 14.7% CAGR (2026–2035). South Korea's digitally advanced health system provides a favorable environment for AI-enabled diagnostic workflows. The market rewards suppliers that can demonstrate technical interoperability, regulatory readiness, and value across both diabetes-related screening and broader ocular-risk assessment within technology-enabled care networks.

Latin America AI-Driven Retinal Screening Device Market Analysis

Latin America is projected to generate USD 387 million by 2035 and expand at approximately 13.7% CAGR (2026–2035). Latin American demand is driven by the need to close chronic-disease screening gaps while working within uneven public-health infrastructure and budget constraints. Portable systems, local distribution partnerships, and service models that support community outreach are likely to be more important than premium device specifications alone.

Brazil

Brazil generated USD 64 million in 2025 and is projected to expand at approximately 13.2% CAGR (2026–2035). Brazil is the region's primary market for retinal AI because it combines scale, a large chronic-disease burden, and both public and private procurement channels. Suppliers must balance the requirements of resource-constrained public programs with the demand for integrated, higher-value diagnostic platforms among private providers.

Mexico

Mexico is projected to generate USD 115 million by 2035 and expand at approximately 14.8% CAGR (2026–2035). Mexico's market is supported by a large diabetes burden and a growing focus on preventive care in urban hospital and clinic networks. Commercial progress will depend on reliable market access, provider education, and technologies that can operate across both private-sector facilities and broader community-health programs.

Argentina

Argentina accounted for a 13% share of Latin American revenue in 2025 and is projected to reach USD 51 million by 2035. Argentina's established urban ophthalmology base provides an initial platform for AI-enabled screening and diagnostic support. Economic volatility creates procurement sensitivity, which may favor subscription-oriented and software-led models that reduce upfront capital requirements while allowing providers to scale usage gradually.

Middle East & Africa AI-Driven Retinal Screening Device Market Analysis

Middle East & Africa is projected to generate USD 258 million by 2035 and expand at approximately 15.1% CAGR (2026–2035). Middle East & Africa combines premium digital-health investment in Gulf markets with substantial unmet screening needs across lower-resource settings. The region therefore supports two distinct models: integrated hospital platforms for advanced health systems and portable, cost-conscious deployments for mobile and community programs. National health initiatives can materially accelerate adoption when they incorporate retinal screening into chronic-disease strategies.

Saudi Arabia

Saudi Arabia generated USD 28 million in 2025 and is projected to expand at approximately 15.7% CAGR (2026–2035). Saudi Arabia's health transformation agenda creates a favorable setting for retinal AI because chronic-disease prevention, digital infrastructure, and centralized investment priorities can reinforce one another. Vendors with local partnerships and implementation capability are likely to benefit as screening is embedded more deeply in primary-care and population-health programs.

UAE

The UAE generated USD 20 million in 2025 and is projected to reach USD 80 million by 2035. The UAE offers a receptive environment for advanced medical AI through its well-funded public and private care sectors and policy emphasis on healthcare innovation. Commercial success will depend on demonstrating clinical value, integration readiness, and patient-data governance that meets the expectations of sophisticated provider organizations.

South Africa

South Africa is projected to generate USD 58 million by 2035 and accounted for a 24% share of Middle East & Africa revenue in 2025. South Africa serves as an important entry market for suppliers seeking wider Sub-Saharan African reach because it combines a comparatively developed private healthcare sector with significant public-health need. The market favors deployment approaches that accommodate constrained public budgets while leveraging private-sector capacity for early commercial adoption and clinical validation.

AI-Driven Retinal Screening Device Market Share & Competitive Landscape

The AI-Driven Retinal Screening Device Market share structure remains fragmented, with the top five companies collectively holding approximately 9.1% of global market revenue in 2025. Competition spans hardware incumbents, pure-play diagnostic software developers, integrated device-AI providers, and regional specialists. Market leadership is therefore determined less by a single algorithm and more by regulatory coverage, installed-base access, reimbursement alignment, workflow integration, and channel reach.

Topcon Healthcare held a 5.8% revenue share in 2025. Topcon Healthcare's position reflects the advantage of an established ophthalmic hardware footprint combined with an expanding digital-platform strategy. Its opportunity is to connect imaging hardware, AI-enabled interpretation, and provider workflow across clinic networks, while its acquisition activity strengthens access to specialized retinal analytics and broader disease-management use cases.

Airdoc Technology held a 1.4% global market share in 2025. Airdoc Technology is positioned as a multi-indication retinal AI platform provider with particular relevance in China's healthcare environment. Its strategic challenge is to convert domestic operating experience into a repeatable international market-access model while maintaining relevance across varied regulatory, reimbursement, and provider-integration conditions.

Digital Diagnostics held a 0.7% global share in 2025. Digital Diagnostics retains strategic importance because autonomous diabetic retinopathy screening has become a reference point for broader point-of-care retinal AI deployment. Its competitive relevance rests on the ability to deepen provider adoption, demonstrate durable real-world workflow value, and extend beyond early implementation settings without diluting clinical rigor.

Eyenuk and AEYE Health remain clinically differentiated competitors in autonomous AI screening. Eyenuk's multi-jurisdiction positioning supports broader platform deployment, while AEYE Health's portable-screening orientation addresses the need for retinal assessment in decentralized care settings. Across the wider market, evolucare, EyRIS, Forus Health, HEART EYE, iCare, identifeye HEALTH, MONA.health, remidio, RetinaLyze, Retmarker, Visionix, and other regional participants compete through specialized modality, care-setting, distribution, and geography strategies. Competitive intensity is likely to increase as vendors seek to combine clearance breadth, data-governance capability, service infrastructure, and evidence generation into defensible provider relationships.

Recent Industry Developments

Topcon Healthcare Acquires RetInSight GmbH (May 2, 2025): Topcon Healthcare completed the acquisition of RetInSight GmbH, adding OCT-based AI capabilities for retinal disease detection and monitoring to its digital eye-care portfolio. The transaction reinforces Topcon's strategy of combining imaging hardware, connected clinical workflows, and specialized AI analytics across retinal-care pathways. ^{[5]Eyenuk. “Eyenuk Secures World's First National Health System Deployment of Autonomous AI Eye Screening Technology.” globenewswire.com}

Eyenuk Secures National Health System Deployment in Norway (September 17, 2025): Eyenuk announced the selection of its EyeArt autonomous AI eye-screening system by South-Eastern Norway Regional Health Authority through a national procurement process. The deployment illustrates the potential for AI retinal screening to move from site-level implementation toward system-scale public-health adoption. ^{[6]AEYE Health. “AEYE Health and Ford Medical Partner to Bring Fully Autonomous, Reimbursable AI Diabetic Eye Exam Screening Solutions to Pharmacies.” prnewswire.com}

AEYE Health and Ford Medical Expand Pharmacy Distribution (July 15, 2025): AEYE Health announced a partnership with Ford Medical to distribute its autonomous diabetic retinopathy screening solution through pharmacies and non-acute care providers in the U.S. The development expands the commercial relevance of portable retinal AI in consumer-accessible and decentralized screening channels.